´Ù¹ß¼º °ñ¼öÁ¾¿¡¼ Lenalidomide Ä¡·á ÈÄ ¹ß»ýÇÑ ÀÌÂ÷¼º ¿ø¹ß Á¾¾ç 1¿¹
A Case of Secondary Primary Malignancy after Lenalidomide Therapy for Multiple Myeloma
´ëÇѳ»°úÇÐȸÁö 2014³â 86±Ç 3È£ p.353 ~ p.356
ÀÌÇýÁ¤(Lee Hye-Jung) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±èÀº¼®(Kim Eun-Seok) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÈ£Áø(Lee Ho-Jin) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
°»óÇö(Kang Sang-Hyeon) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹ÚÀÎö(Park In-Chul) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÌÁöÇö(Lee Ji-Hyun) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è¼ºÇö(Kim Sung-Hyun) - µ¿¾Æ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
´Ù¹ß°ñ¼öÁ¾ ȯÀÚ¿¡¼ Lenalidomide Ä¡·á·Î ÀÎÇØ ¹ß»ýÇÑÀÌÂ÷¼º ¿ø¹ß Á¾¾çÀº ÁÖ¿ä ÇÕº´ÁõÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ±×·¯³ª ÀÌ¿¡ ´ëÇÑ Á÷Á¢ÀûÀÎ º´Å»ý¸®¿Í Àΰú°ü°è¿¡ ´ëÇÑ ¿¬±¸´Â ºÎÁ·ÇÑ ½ÇÁ¤À̳ª ±¹³»¿¡¼µµ lenalidomideÀÇ »ç¿ë·®ÀÌ Á¡Â÷ Áõ°¡ÇϹǷΠ°°ÀÌ lenalidomide¸¦ »ç¿ëÇϴ ȯÀÚ¿¡¼ ÀÌÂ÷¼º ¿ø¹ß Á¾¾çÀÇ ¹ß»ýÀ» º¸´Ù ÁÖÀÇ ±í°Ô °üÂûÇØ¾ß ÇÏ°Ú´Ù.
Lenalidomide, an orally administered immune-modulating drug, has several mechanisms of action against multiple myeloma (MM). However, the mechanisms of action of immune-modulating drugs are not understood completely. Lenalidomide maintenance therapy prolongs the time to progression and increases the overall survival in patients with MM. However, secondary primary malignancy (SPM) has been noted as a serious adverse event in patients with MM treated with lenalidomide. Lenalidomide treatment is not covered by insurance. Consequently, physicians have little experience with the adverse events of lenalidomide treatment in patients with MM. Here, we describe a case of breast cancer after lenalidomide treatment for MM. To our knowledge, this is the first report of a lenalidomide-associated SPM in Korea. The risk factors associated with lenalidomide-associated SPM should be considered carefully when implementing chemotherapy regimens in patients with MM.
Å°¿öµå
´Ù¹ß¼º °ñ¼öÁ¾, ÀÌÂ÷¼º ¿ø¹ßÁ¾¾ç
Multiple myeloma, Lenalidomide, Breast cancer, Secondary primary malignancy
KMID :
0882420140860030353
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)